European Commission Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) for Patients With Certain Types of Endometrial Carcinoma

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. PRIM
3. DPZ
4. ACN
5. DFTX
6. IBM
7. META
8. AISP
9. KFY
10. SPY

Go back to European Commission Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) for Patients With Certain Types of Endometrial Carcinoma
Merck & Co. (NYSE: MRK) Delayed: 115.48 --0 (-0%)
Previous Close $115.48    52 Week High $65.46 
Open $115.48    52 Week Low $47.97 
Day High $115.48    P/E 78.56 
Day Low $115.48    EPS $1.47 
Volume 12,902